Wigzell Hans Lennart Rudolf 4
4 · Sarepta Therapeutics, Inc. · Filed Mar 11, 2024
Insider Transaction Report
Form 4
Wigzell Hans Lennart Rudolf
Director
Transactions
- Sale
Common Stock
2024-03-08$123.85/sh−3,155$390,747→ 34,685 total - Sale
Common Stock
2024-03-08$123.10/sh−11,745$1,445,810→ 22,940 total - Exercise/Conversion
Common Stock
2024-03-08$13.90/sh+15,000$208,500→ 37,840 total - Sale
Common Stock
2024-03-08$122.39/sh−100$12,239→ 22,840 total - Exercise/Conversion
Stock Option (right to buy)
2024-03-08−15,000→ 0 totalExercise: $13.90From: 2016-02-27Exp: 2035-02-27→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.6 to $124.6, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $122.65 to $123.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.